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Abstract  
 
The WHO’s list of essential medicines list for migraine only includes paracetamol, aspirin, 
ibuprofen and propranolol at present. In the past few years Lifting The Burden has been striving to 
include triptans as a group. It is a clinical reality indeed that patients may not respond to analgesics 
and NSAIDs, but may be triptan-responders. The benefit to tolerability ratio of triptans favors oral 
triptans in acute migraine treatment, but we illustrate why subcutaneous sumatriptan is the triptan of 
choice in acute cluster headache treatment. The individual respons to prophylactic treatment is quite 
variable, based on individual pharmacokinetic and pharmacodynamic differences. Tailoring of 
drugs to patients is important in clinical practice. Barriers to optimal drug treatment of headache 
disorders include undertreatment and mismanagement, despite existing guidelines. Medication-
overuse headache has been described in a number of headache disorders, but is most commonly 
encountered in migraine patients. 
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Established Knowledge  
 
The treatment of headaches begins with making a diagnosis, explaining it to the patient, and 
developing a treatment plan taking into account the severity and frequency of the headache. 
Headache is most often a very painful and bothersome disorder in which drug treatment is needed 
acutely. In addition, when migraine, cluster headache and tension-type headache are occurring 
frequently, preventive daily intake of a drug may be needed. 
Acute drugs for migraine are specific drugs, such as triptans and ergot alkaloids, and non-specific 
drugs such as paracetamol, aspirin and other NSAIDs. For acute treatment of cluster headache only 
quickly absorbed triptans are effective. Tension-type headaches are treated acutely with analgesics. 
Triptans are not effective in episodic tension-type headache (Brennum et al. 1996). 
For prophylaxis of migraine several types of drugs can be used, including β-blockers, anti-epileptics 
and calcium channel blockers (Steiner et al. 2007). Only one drug, methysergide, was designed for 
migraine prophylaxis and it is rarely used because of risk of severe side effects. The prophylactic 
drug of first choice in cluster headache is verapamil. In frequent and chronic tension-type headache 
tricyclic antidepressant drugs are used. 
Worldwide the use of drugs is heavily dependent on the WHO’s list of essential drugs and this list 
will be discussed. Cost is still an important factor, especially with the triptans for which the patent 
has not expired. With all acute drugs for headache there is the risk for overuse with resulting daily 
headache (see Chapter 47). Headache disorders are often chronic disorders wherefore tolerability 
and safety are important issues. 
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WHO’s essential medicines list for migraine 
Table 1 
  7 Antimigraine medicines  
  7.1 For treatment of acute attack  
       Acetylsalicylic acid Tablet: 300 mg to 500 mg 
       Ibuprofen [c] Tablet: 200 mg; 400 mg 
       Paracetamol Oral liquid: 125 mg/5 ml [c] 
Tablet 300 mg to 500 mg 
  7.2 For prophylaxis  
       Propranolol Tablet: 20 mg; 40 mg (hydrochloride) 
 
Legend Table 1: WHO’s essential medicines list for migraine (16th Edition, revised March 2010); 
[c] signifies that there is a specific indication for restricting its use to children; Source: 
http://www.who.int/medicines/publications/essentialmedicines/en/index.html 
 
The WHO List of Essential Medicines (revised March 2010) is shown in Table 1 with respect to 
migarine. Lifting The Burden, The Global Campaign to Reduce the Burden of Headache 
Worldwide, has in the last years argued that triptans as a group should be included in the list for 
migraine. WHO has, however, argued that as long as triptans have not been demonstrated to be 
superior to aspirin there is no need for adding the triptans to the list. Thus a meta-analysis of 3 
RCTs provided evidence that effervescent aspirin 1,000 mg is as effective as sumatriptan 50 mg for 
the acute treatment of migraine attacks, and that both are superior to placebo (Lampl et al. 2007). 
This is illustrated by the meta-analysis results for pain relief at 2 hours, defined as a decrease in 
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headache from moderate or severe to none or mild after 2 hours, amounting to 52 % (95% CI: 47 – 
57%) for effervescent aspirin 1,000 mg which is quite comparable to sumatriptan 50 mg (47%, 95% 
CI: 40-52%), and both are significantly superior to placebo (34%, 95% CI: 29-39%). These results 
seemingly demonstrate that the two groups of drugs, triptans and NSAIDs, are equivalent in 
migraine treatment (Lampl et al. 2007). Comparisons of oral triptans with other classes of acute 
treatments are few, and in general differences between active treatments on the primary endpoints 
were not dramatic (Lipton et al. 2004). Nevertheless these data have been questioned as there is a 
discrepancy with experience in clinical practice (Lipton et al. 2004). We are as clinicians confronted 
every day with migraine patients that do not respond to analgesics or NSAIDs. There is thus the 
need for more migraine-specific drugs such as triptans or ergot alkaloids. Regardless of this a drug 
like effervescent aspirin should be the drug of first choice in migraine, but triptans or ergot 
alkaloids should be available for those patients unresponsive to aspirin. For most migraine sufferers 
requiring a specific anti-migraine treatment, a triptan is generally a better option from both an 
efficacy and side-effect perspective (Tfelt-Hansen et al. 2000). The recommended doses of 20 mg 
and 40 mg for propranolol are not in agreement with the literature on migraine prophylaxis with 
propranolol in randomised clinical trials (RCTs) (Tfelt-Hansen and Rolan 2006). The most 
commonly used dose of propranolol in these RCTs is 160 mg per day and the WHO list should be 
changed to propranolol 40 mg and 80 mg. 
 
Headache in general, and migraine in specific, are probably the stepchild in pain management. The 
use of drugs in headache and migraine should be evidence-based. “Evidence-based medicine is the 
conscientious, explicit, and judicious use of current best evidence in making decisions about the 
care of individual patients”.”The practice of evidence-based medicine means integrating individual 
clinical expertise with the best available external clinical evidence from systematic research” 
(Sackett et al. 1996). Evidence-based medicine is more than just meta-analyses of drugs and 
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procedures. WHO seemingly does not understand the second part of evidence-based medicine: the 
integration of individual clinical expertise into the decision. What do you do when you have a 
migraine patient who has unsuccessfully tried aspirin for three migraine attacks. As shown in the 
meta-analysis even with the optimal aspirin, effervescent aspirin 1,000 mg, 50% of the patients 
don’t respond with headache relief and 70% are not pain free after 2 hours (Lampl et al. 2007). 
Most patients with headache worldwide self-medicate for migraine, using aspirin and paracetamol 
and thus following the WHO recommendations. In some countries a few triptans are over the 
counter drugs (Tfelt-Hansen and Steiner 2007). Triptans are currently, however, only used by 10-
15% of migraine patients in Denmark and UK (Tfelt-Hansen and Steiner 2007). 
 
Benefit/tolerability ratio for specific migraine drugs 
 
The best available evidence comes from systematic reviews (or meta-analyses) of RCTs. In 
migraine there are several meta-analyses, mostly on triptans (Tfelt-Hansen et al. 2000; Ferrari et al. 
2001; McCrory and Gray 2003; Pascual 2004; Saxena and Tfelt-Hansen 2006). The efficacy is most 
often well described in RCTs whereas adverse events are currently reported in different ways. This 
makes comparison of tolerability in systematic reviews problematic. A practical example on the 
choice between the two administration forms of sumatriptan, oral and subcutaneous, plus the choice 
in cluster headache, is given in Table 2. As is shown subcutaneous sumatriptan 6 mg is both more 
effective and causes more adverse events than the oral form of sumatriptan 100 mg. Subcutaneous 
sumatriptan is also more quickly effective (relevant effect after 20 min) than oral sumatriptan 
(relevant effect after 60 min) (Saxena and Tfelt-Hansen 2006). Apparently, the simple 
benefit/tolerability is better for oral sumatriptan (32%/16% = 2) than subcutaneous sumatriptan 
(51%/33% = 1.5) but clinical treatment is not that simple. Most patients prefer the oral route of 
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administration. The price of subcutaneous sumatriptan 6 mg is very high, 37 € versus 1 € for 
sumatriptan 50 mg (current prices in Denmark). In cluster headache the situation is different. The 
attack is very severe but short-lasting. So the treatment should work quickly with a high response 
rate. Even if intranasal sumatriptan 20 mg and zolmitriptan 5 mg are statistically superior to 
placebo, it is only subcutaneous sumatriptan 6 mg which has an early clinically relevant effect 
(Table 2). 
 
In prophylaxis of migraine adverse events are in our experience the most frequent reasons for 
stopping the treatment. One should be aware of the fact that drugs results in very variable plasma 
levels, often 5 to 10 fold differences among subjects. In addition, there is a pharmacodynamic 
variability (Tfelt-Hansen and Edvinsson 2007). This variability is especially important in migraine 
prophylaxis. The dictum should be “start low, go slow”. Usually we start out with ¼ to ½ of the 
dose used in RCTs and then slowly over weeks to months increase the dose depending on efficacy 
and tolerability. Such a tailoring of the drug to the individual patients can usually not be done in 
RCTs. 
 
These examples hopefully illustrate that the benefit/tolerability ratio is content dependent and it is 
the responsibility of the physician to try optimize the treatment of the individual patient. 
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Table 2.  
Data from randomised clinical trials (RCTs) Data not evident from RCTs and personal 
clinical experiences 
Sumatriptan 100 mg is superior to placebo in 
RCTs  with a therapeutic gain (TG) of 32% 
(Tfelt-Hansen et al. 2000). There are 16% (95% 
CI: 13-19%) more adverse events after 
sumatriptan than after placebo. Sumatriptan 100 
mg begins to have a clinically relevant effect 
after 60 min with a maximum after 120 min.  
Sumatriptan 6 mg subcutaneous (SC) has a TG 
of 51%. There are 33% (95% CI: 29-37%) more 
adverse events after sumatriptan 6 mg SC than 
after placebo. Sumatriptan 6 mg SC begins to 
have a clinically relevant effect after 20 min 
with a maximum effect after 60 min. 
 The plasma level of sumatriptan varies 
considerably ( 4-10 fold) after oral 
administration. Most patients prefer the oral 
route of administration. Sumatriptan 6 mg SC is 
very costly (37 €) versus sumatriptan tablets 50 
mg (1 €). 
Migraine 
Efficacy/tolerability ratio: 
Both oral (TG: 32%) and SC sumatriptan (TG: 
51%) are effective. Sumatriptan 6 mg SC causes 
more adverse events than oral sumatriptan (33% 
versus 16% more than placebo). 
 
Because of the more frequent adverse events 
after sumatriptan 6 mg SC the oral form has 
clinically the best efficacy/tolerability ratio in 
migraine. The oral form is also much cheaper (1 
€ versus 30 €). If very quick effect is needed 
sumatriptan 6 mg SC is better than the oral 
form. 
Cluster headache 
Sumatriptan 6 mg SC is effective in cluster 
headache: within 15 min 74% of sumatriptan 
treated attacks responded (no or mild headache) 
versus 26% of placebo treated attacks. After 
nasal sumatriptan 20 mg 57% responded after 
30 min versus 26% after placebo. Nasal 
zolmitriptan 5 mg resulted in 48% response 
after 30 min versus 19% response after placebo. 
Given the short duration and severity of attacks, 
rapidity of action is a crucial factor. Sumatriptan 
6 mg SC has quicker onset of action and is more 
effective than the nasal triptans. SC sumatriptan 
is generally the drug of first choice. 
Legend Table 2: A practical example of the choice between two administration forms of triptans 
based on the benefit/risk ratio 
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Barriers to optimal drug choice in the treatment of headache disorders 
 
Underdiagnosis and diagnostic delay have been well documented in a number of headache 
disorders, including common syndromes such as migraine and cluster headache (Lipton et al. 2001; 
Bahra and Goadsby 2004). Even when a correct diagnosis has been made, undertreatment and 
mismanagement have been observed despite the existence of guidelines for clinical practice (May et 
al. 2006; Steiner et al. 2007; Evers et al. 2009). Patients may receive acute treatment, but no 
prevention (when indicated) and vice versa. Ineffective acute drugs or prophylactic drugs may have 
been proposed to patients. The proportion of IHS-defined migraineurs using only over-the-counter 
medications to treat their headaches was 57% in the American Migraine Study II (Lipton et al. 
2001). There was a clear underuse of migraine prevention in the American Migraine Prevalence and 
Prevention study (Diamond et al. 2007). A significant fraction of cluster headache patients never 
have had access to SC sumatriptan or high-flow oxygen, both first line acute treatments according 
to current recommendations (May et al. 2006; Van Alboom et al. 2009). Cluster headache patients 
may receive ineffective prophylactic drugs such as propranolol, carbamazepine or amitriptyline 
(Van Alboom et al. 2009). Medication-overuse headache is a major public health concern and 
affects 0.7% to 1.7% of the population (Evers and Marziniak 2010). Medication-overuse headache 
has been described in a variety of headache disorders including tension-type headache, migraine 
and cluster headache (Diener and Limmroth 2004; Paemeleire et al. 2006). In principle, all acute 
drugs for the treatment of headache could cause MOH (Evers and Marziniak 2010).  
Appropriate treatment may have been advised, but patients may lapse from care (Edmeads 2006). It 
is however important that resources are available to guarantee adequate follow-up of patients to 
ensure that optimum treatment has been established (Steiner et al. 2007). Stepped care guidelines 
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are available in acute migraine treatment (Steiner et al. 2007), and we have made the case for 
triptans in non-responders to NSAIDs in acute migraine. 
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Current Research  
Not applicable to this chapter
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